AstraZeneca plc (AZN) Ordinary US$0.25
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
AstraZeneca's Tagrisso recommended for EU approval
18 November 2024 09:11
(Sharecast News) - Drugmaker AstraZeneca said on Monday that its Tagrisso asset had received a recommendation for EU approval on the back of LAURA Phase III trial results, which revealed it had extended...
-
Sunday newspaper round-up: Kursk, AstraZeneca, BAE Systems
17 November 2024 18:14
(Sharecast News) - America's President has authorised Ukraine to employ long-range ATACMS supplied by the US to strike targets inside Russia. More specifically, Kyiv will now be allowed to strike...
-
Director dealings: AstraZeneca CEO ups stake
15 November 2024 16:11
(Sharecast News) - AstraZeneca revealed on Friday that chief executive officer Pascal Soriot had acquired 20,000 ordinary shares in the FTSE 100-listed drugmaker.
-
London close: Stocks end turbulent week in the red
15 November 2024 15:21
(Sharecast News) - London stocks ended Friday in negative territory, weighed down by losses in pharmaceutical shares and a surprise slowdown in UK economic growth during the third quarter.
-
London close: Stocks sink as UK jobless rate rises
12 November 2024 16:39
(Sharecast News) - London stocks fell sharply on Tuesday as investors digested recent UK employment data alongside broader market reactions to Donald Trump's US presidential victory last week.
-
AstraZeneca upgrades full-year guidance amid strong momentum
12 November 2024 07:17
(Sharecast News) - AstraZeneca upgraded its full-year revenue and earnings per share guidance on Tuesday, citing strong growth across key therapy areas and robust financial results for the first nine months...
-
AstraZeneca "excited" by positive results in Tezspire clinical trial
8 November 2024 07:19
(Sharecast News) - AstraZeneca has announced positive high-level results from a phase III for its Texspire treatment for nasal polyps.
-
AstraZeneca says does not comment on media reports as shares slump
5 November 2024 17:18
(Sharecast News) - AstraZeneca said on Tuesday that it does not comment on speculative media reports, in response to a sharp drop in its share price.
-
AstraZeneca China president under investigation
30 October 2024 13:37
(Sharecast News) - Drugmaker AstraZeneca revealed on Wednesday that Leon Wang, the president of AstraZeneca China, was under investigation by Chinese authorities.
-
AstraZeneca's nerve damage treatment recommended for approval in EU
21 October 2024 07:10
(Sharecast News) - Pharma titan AstraZeneca has announced that its Wainzua nerve damage treatment has been recommended for approval in the EU.
-
Hutchmed reports positive results from AstraZeneca lung cancer collaboration
16 October 2024 11:41
(Sharecast News) - Hutchmed China announced positive results from its Savannah phase two trial on Wednesday, which studied the combination of 'Tagrisso', or osimertinib, and 'Orpathys',...
-
AstraZeneca enters into exclusive license agreement with CSPC
7 October 2024 10:16
(Sharecast News) - Drugmaker AstraZeneca has entered into an exclusive license agreement with CSPC Pharmaceutical to advance the development of a pre-clinical novel lipid-lowering therapy.
Company announcements Announcements
-
Tagrisso recommended for EU approval - LAURA
18 November 2024 07:00
AstraZeneca
-
Director/PDMR Shareholding
15 November 2024 10:00
AstraZeneca
-
Director/PDMR Shareholding
13 November 2024 16:00
AstraZeneca
-
AstraZeneca invests $3.5 billion in US
12 November 2024 07:10
AstraZeneca
-
KOMET Phase III trial met primary endpoint
12 November 2024 07:05
AstraZeneca
-
9M and Q3 2024 Results
12 November 2024 07:00
AstraZeneca
-
Dato-DXd new BLA submitted, NSQ BLA withdrawn
12 November 2024 07:00
AstraZeneca
-
Tezspire nasal polyps trial met primary endpoints
8 November 2024 07:00
AstraZeneca
-
AZN share price movement
5 November 2024 16:49
AstraZeneca
-
Total Voting Rights
1 November 2024 15:00
AstraZeneca
-
AZN China President under investigation
30 October 2024 13:00
AstraZeneca
-
Wainzua recommended for approval in the EU
21 October 2024 07:00
AstraZeneca
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.